Literature DB >> 33616788

Molecular characterization of clinical carbapenem-resistant Enterobacterales from Qatar.

Fatma Ben Abid1,2,3, Clement K M Tsui4,5,6, Yohei Doi7,8, Anand Deshmukh9, Christi L McElheny7, William C Bachman7, Erin L Fowler7, Ahmed Albishawi10,11, Kamran Mushtaq12, Emad B Ibrahim9, Sanjay H Doiphode9, Manal M Hamed9, Muna A Almaslmani10,11, Abdullatif Alkhal10,11, Adeel A Butt4,12, Ali S Omrani10,11,13.   

Abstract

One hundred forty-nine carbapenem-resistant Enterobacterales from clinical samples obtained between April 2014 and November 2017 were subjected to whole genome sequencing and multi-locus sequence typing. Klebsiella pneumoniae (81, 54.4%) and Escherichia coli (38, 25.5%) were the most common species. Genes encoding metallo-β-lactamases were detected in 68 (45.8%) isolates, and OXA-48-like enzymes in 60 (40.3%). blaNDM-1 (45; 30.2%) and blaOXA-48 (29; 19.5%) were the most frequent. KPC-encoding genes were identified in 5 (3.6%) isolates. Most common sequence types were E. coli ST410 (8; 21.1%) and ST38 (7; 18.4%), and K. pneumoniae ST147 (13; 16%) and ST231 (7; 8.6%).
© 2021. The Author(s).

Entities:  

Keywords:  CRE; Carbapenemase; Enterobacterales; KPC; Middle East; NDM; OXA; Qatar; VIM

Year:  2021        PMID: 33616788      PMCID: PMC8295067          DOI: 10.1007/s10096-021-04185-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


Introduction

Considerable variations exist in the epidemiology of carbapenemases in Enterobacterales from different parts of the world [1]. Awareness of the locally prevalent carbapenemases is relevant to the appropriate selection of antimicrobial therapy for carbapenem-resistant Enterobacterales (CRE) infections [2]. Moreover, the molecular epidemiology of CRE could help guide control efforts. The aim of this study was to identify the predominant carbapenemases in CRE from Qatar and to elucidate their molecular epidemiology.

Methods

All carbapenem-resistant Enterobacterales isolates from clinical specimens received at Hamad Medical Corporation Microbiology Department during the period between April 2014 and November 2017 were included. The department provides diagnostic microbiology services for all public hospitals in Qatar. Laboratory methods for bacterial identification, antimicrobial susceptibility testing, whole genome sequencing and analysis are described in the supplementary data file.

Results

A total of 149 non-repetitive CRE clinical isolates from 146 patients were included. The median patient age was 57 years (range, 3 months–97 years), and 77 (52.7%) were males. Diabetes mellitus (73; 50%) and chronic kidney diseases (39; 26.7%) were the most frequent co-existing medical conditions. Nineteen (12.8%) isolates were recovered from samples obtained within the first 24 h of hospitalization. Nearly one-fifth of the patients (25, 17.1%) had entered the country from overseas within 30 days prior to CRE isolation. Further demographic and clinical details are provided in Table 1 and in Table S1 in the supplementary data file.
Table 1

Patient demographics and clinical outcome

VariableNumber (%)(149 isolates from 146 patients)
Demographics
Median age in (range)57 years (3 months–97 years)
Male sex77 (52.7%)
Nationality of origin*
Eastern Mediterranean Region96 (65.7%)
South East-Asia Region41 (28.1%)
European Region3 (2%)
Regions of the Americas1 (0.7%)
Comorbidities
Diabetes mellitus73 (50%)
Chronic kidney disease39 (26.7%)
Congestive heart failure20 (13.7%)
Chronic liver disease9 (6.1%)
Chronic airway disease7 (4.8%)
Solid malignancy20 (13.7%)
Hematological malignancy11 (7.5%)
Solid organ transplant11 (7.5%)
Hematopoietic stem cell transplant4 (2.7%)
Active chemotherapy within 30 days of CRE isolation16 (10.9%)
Anti-TNF therapy within 30 days of CRE isolation15 (10.3%)
Corticosteroid therapy within 30 days of CRE isolation15 (10.3%)
Carbapenem therapy within 30 days of CRE isolation45 (30.8%)
Invasive procedure within 30 days of CRE isolation
Surgical procedure41 (28.1%)
Central line insertion29 (19.8%)
Urinary catheterization29 (19.8%)
Vascular stent insertion11 (7.5%)
Other risk factors for CRE infection
Presence of central venous catheter42 (28.7%)
Total parenteral nutrition5 (3.4%)
Mechanical ventilation41 (28.1%)
Travel within 30 days of CRE isolation25 (17.1%)
Site of isolation
Urinary tract41 (28.1%)
Blood stream33 (22.6%)
Lower respiratory tract17 (11.6%)
Skin and soft tissue8 (5.5%)
Others14 (9.6%)
Clinical outcome
Death within 30 days from CRE isolation34 (23.3%)
Recurrence with 30 days38 (26%)

*World Health Organization Regions. CRE, carbapenem-resistant Enterobacterales

Patient demographics and clinical outcome *World Health Organization Regions. CRE, carbapenem-resistant Enterobacterales The most frequent species were Klebsiella pneumoniae (81; 54.4%) and Escherichia coli (38; 25.5%) (Table 2), whereas urine (41; 27.5%) and blood (33; 22.1%) were the most frequent site of isolation (Table 1). Thirty-four (23.3%) patients died within 30 days of first CRE isolation. The majority of isolates were susceptible to tigecycline (129; 86.5%), fosfomycin (126; 84.6%), and amikacin (108; 72.4%) (Table S2 in the supplementary data file).
Table 2

Carbapenemase genes detected in the study isolates

Carbapenemase genesAll isolates(n = 149)E. coli(n = 38)K. pneumoniae(n = 81)K. quasipneumoniae(n = 16)E. cloacae(n = 7)Others*(n = 7)
Class A4 (2.7%)04 (4.9%)000
blaKPC-23 (2.0%)-3 (3.7%)---
blaKPC-31 (0.7%)-1 (1.2%)---
Class B64 (43.0%)14 (36.8%)24 (29.6%)16 (100%)6 (85.7%)4 (57.1%)
blaIMP-261 (0.6%)1 (2.6%)----
blaNDM-145 (30.2%)3 (7.9%)22 (27.2%)14 (87.5%)4 (57.1%)2 (28.6%)
blaNDM-57 (4.7%)7 (18.4%)----
blaNDM-61 (0.7%)1 (2.6%)----
blaNDM-75 (3.4%)-1 (1.2%)2 (12.5%)-2 (28.6%)
blaNDM-131 (0.7%)1 (2.6%)----
blaNDM-191 (0.7%)1 (2.6%)----
blaVIM-21 (0.7%)-1 (1.2%)---
blaVIM-42 (1.3%)---2 (28.6%)-
Class D59 (39.6%)21 (55.2%)34 (42%)01 (14.3%)2 (28.6%)
blaOXA-4829 (19.5%)10 (26.3%)16 (19.8%)-1 (12.3%)2§ (28.6%)
blaOXA-18119 (12.8%)10 (26.3%)9 (11.1%)---
blaOXA-23210 (6.7%)-10 (12.3%)---
blaOXA-2441 (0.7%)1 (2.6%)----
Multiple carbapenemases8 (5.3%)1 (2.6%)7 (8.6%)001 (14.3%)
blaNDM-1 + blaKPC-31 (0.7%)-1 (1.2%)---
blaNDM-1 + blaOXA-1812 (1.3%)-2 (2.5%)---
blaNDM-5 + blaOXA-483 (2.0%)-3 (3.7%)---
blaNDM-5 + blaOXA-1812 (1.3%)1 (2.6%)1 (1.2%)---
None14 (9.4%)1 (2.6%)12 (14.8%)--1¶ (12.3%)

*Klebsiella aerogenes (2), Providencia spp. (2), Citrobacter freundii (1), Klebsiella oxytoca (1), and Proteus mirabilis (1)

†Providencia sp. (1), P. mirabilis (1)

‡C. freundii (1), Providencia sp. (1)

§K. oxytoca (1), K. aerogenes (1)

¶K. aerogenes (1)

Carbapenemase genes detected in the study isolates *Klebsiella aerogenes (2), Providencia spp. (2), Citrobacter freundii (1), Klebsiella oxytoca (1), and Proteus mirabilis (1) Providencia sp. (1), P. mirabilis (1) C. freundii (1), Providencia sp. (1) §K. oxytoca (1), K. aerogenes (1) ¶K. aerogenes (1) Genes encoding Class B carbapenemases (i.e., metallo-β-lactamases [MBL]) were detected in 68 (45.8%) isolates, and Class D carbapenemases in 60 (40.3%). The most frequently identified carbapenemase genes were blaNDM-1 (45; 30.2%) and blaOXA-48 (29; 19.5%) (Table 3). KPC-encoding genes were identified in 5 (3.6%) isolates. All 5 patients from whom KPC-producing K. pneumoniae were isolated had received medical care abroad within the preceding 30 days (Table S3 in the supplementary data file). No carbapenemase genes were detected in 14 (9.4%) isolates, and 8 (5.3%) carried more than one carbapenemase genes (Table 2).
Table 3

Study isolates by their sequence type and carbapenemase genes

SpeciesSequence type (number of isolates)Carbapenemase-encoding genes (number of isolates)
E. coli (n = 38)ST10 (2)blaNDM-5 (1), none (1)
ST23 (1)blaOXA-48 (1)
ST38 (7)blaOXA-48 (6), blaOXA-181 (1)
ST58 (1)blaOXA-48 (1)
ST101 (2)blaNDM-1 (1), none (1)
ST131 (1)blaIMP-26 (1)
ST167 (3)blaNDM-1 (1), blaNDM-13 (1), blaNDM-19 (1)
ST361 (1)blaNDM-5 (1)
ST405 (2)blaOXA-48 (1), blaNDM-5 (1)
ST410 (8)blaOXA-181 (7), blaNDM-5 and blaOXA-181 (1)
ST617 (2)blaNDM-5 (2)
ST648 (2)blaOXA-48 (1), blaOXA-244 (1)
ST940 (1)blaNDM-1 (1)
ST1487 (2)blaNDM-5 (1), blaOXA-181 (1)
ST1193 (1)blaNDM-5 (1)
ST8346 (1)blaOXA-181 (1)
Undetermined (1)blaNDM-6 (1)
K. pneumoniae (n = 81)ST4 (1)blaNDM-1 (1)
ST10 (2)blaNDM-5 (1), none (1)
ST11 (5)blaNDM-1 (4), blaKPC-2 (1)
ST14 (2)blaNDM-1 (2)
ST15 (2)blaNDM-1 (1), blaKPC-2 (1)
ST16 (3)blaNDM-1 + blaOXA-181 (1), blaOXA-181 (1), blaOXA-232 (1)
ST17 (1)blaNDM-1 (1)
ST35 (1)blaOXA-181 (1)
ST38 (1)blaOXA-232 (1)
ST39 (3)blaNDM-1 (3)
ST101 (1)None (1)
ST147 (13)blaNDM-1 (4), blaOXA-181 (5), blaOXA-48 (1), blaNDM-1 + blaOXA-181 (1), blaNDM-5 + blaOXA-181 (1), none (1)
ST220 (1)None
ST231 (7)blaOXA-232 (4), blaOXA-48 (1), none (2)
ST252 (1)blaNDM-1 (1)
ST258 (1)blaKPC-3 (1)
ST280 (1)blaOXA-48
ST307 (2)None (2)
ST323 (1)blaOXA-48
ST340 (2)blaNDM-1 (2)
ST376 (1)blaOXA-48
ST383 (4)blaOXA-48 (1), blaNDM-5 + blaOXA-48 (3)
ST395 (2)blaOXA-232 (1), none (1)
ST405 (1)blaOXA-48 (1)
ST420 (2)blaOXA-48 (2)
ST432 (1)blaOXA-48 (1)
ST584 (1)None (1)
ST716 (2)blaOXA-48 (2)
ST873 (1)blaOXA-48 (1)
ST915 (3)blaNDM-1 (3)
ST983 (1)blaOXA-48 (1)
ST985 (1)None (1)
ST1193 (2)blaOXA-48 (1), blaNDM-7 (1)
ST1418 (1)blaOXA-181 (1)
ST1626 (1)blaOXA-48 (1)
ST2096 (2)blaOXA-232 (2)
ST3311 (1)None (1)
ST5029 (1)blaKPC-2 (1)
ST5030 (1)blaOXA-232 (1)
ST5031 (1)blaOXA-181 (1)
Undetermined (2)blaKPC-3 + blaNDM-1 (1), blaVIM-2 (1)
K. quasipneumoniae (n = 16)ST196 (9)blaNDM-1 (9)
ST1416 (4)blaNDM-1 (4)
ST1584 (1)blaNDM-7 (1)
ST1998 (1)blaNDM-7 (1)
Undetermined (1)blaNDM-1 (1)
E. cloacae (n = 7)ST66 (1)blaOXA-48 (1)
ST113 (1)blaNDM-1 (1)
ST511 (1)blaNDM-1 (1)
ST609 (1)blaNDM-1 (1)
ST78 (3)blaNDM-1 (1), blaVIM-4 (2)
K. aerogenes (n = 2)ST93 (1)None (1)
Undetermined (1)blaOXA-48 (1)
Providencia sp. (n = 2)Undetermined (1)blaNDM-1 (1), blaNDM-7 (1)
C. freundii (n = 1)Undetermined (1)blaNDM-7 (1)
K. oxytoca (n = 1)Undetermined (1)blaOXA-48 (1)
P. mirabilis (n = 1)Undetermined (1)blaNDM-1 (1)
Study isolates by their sequence type and carbapenemase genes The included E. coli isolates belonged to 16 different sequence types, the most frequent of which were ST410 (8; 21.1%) and ST38 (7; 18.4%). On the other hand, K. pneumoniae isolates represented 40 different sequence types, most frequently ST147 (13; 16%) and ST231 (7; 8.6%). K. quasipneumoniae belonged mainly to ST196 (9; 56.3%) and ST1416 (4; 25%). Except for K. quasipneumoniae, strains with the same sequence type mostly possessed different carbapenemase genes (Table 3).

Discussion

Typical risk factors for multidrug-resistant Gram-negative infections were highly prevalent in the patients from whom the isolates were retrieved [3]. The observed 30-day all-cause mortality of 23.3% is consistent with existing literature describing clinical outcomes in patients with CRE infections [4]. The most common carbapenemase genes in this study were those encoding MBL, especially NDM-1 and NDM-7. Effective antimicrobial therapy options for MBL-producing Enterobacterales are very limited and their management remains particularly challenging [5]. NDM enzymes are established in CRE from the Arabian Peninsula [6, 7]. Given that more than half of the country’s residents originate from the Indian Subcontinent, the high prevalence of NDM in CRE from Qatar is not surprising. NDM genes are commonly co-carried with other carbapenemase genes [5]. In this study, NDM genes were present in all eight isolates that possessed multiple carbapenemase genes. VIM-producing Enterobacterales are endemic in Greece and Eastern Europe, but are otherwise relatively rare [8]. In this study, VIM genes were present in two E. cloacae isolates. VIM carbapenemases have also been reported in K. pneumoniae and E. cloacae from Turkey, Kuwait, and Saudi Arabia [7, 9, 10]. blaIMP-26 was detected in a single E. coli isolate in this study. IMP-producing Enterobacterales are endemic in Japan, but are rarely detected in CRE from the Middle East [11]. OXA-48-like β-lactamases are wide-spread in the Arabian Peninsula and the Middle East [6]. Likewise, nearly two-fifth of isolates in this study possessed OXA-encoding genes. Some, but not all, Class D β-lactamases have carbapenemase hydrolyzing activity [12]. Notably, 30.2% of our isolates, all of which possessed OXA-48-like genes, were susceptible to meropenem. As previously well-documented, nonsusceptibility to ertapenem is often the most sensitive indicator of carbapenemase production [13]. Similar to previous reports of frequent co-presence of OXA-48-like enzymes with MBL, seven out of eight isolates with multiple carbapenemase genes in this study possessed genes encoding NDM and OXA-48-like enzymes [12, 14]. OXA-181 and OXA-232 are OXA-48-like carbapenemases. OXA-181 differs from OXA-48 by four amino acids and, like NDM, its origin is epidemiologically linked to the Indian subcontinent [12]. In the Middle East region, OXA-181 was previously identified in CRE from Lebanon and Oman [14, 15]. OXA-232 differs from OXA-48 by five amino acids substitutions, and from OXA-181 by one mutation [12]. It was first reported in K. pneumoniae from France, but has since been reported from many parts of the world including South Asia and North Africa [16, 17]. Interestingly, OXA-232 is often present in K. pneumoniae ST231 [18]. Four out of 10 OXA-232-producing K. pneumoniae in our study belonged to this sequence type. One meropenem-susceptible E. coli isolate in this report possessed blaOXA-244. OXA-244 is a single-point mutation derivative of OXA-48, with weaker carbapenem hydrolyzing activity [12]. First described in K. pneumoniae from Spain, OXA-244 is now disseminated in E. coli in many countries in Western Europe [19]. An important finding in this study is the presence of KPC-encoding genes in five K. pneumoniae isolates, all of which were recovered from patients who had recently received medical care in KPC-endemic regions. KPC enzymes have historically been rare in the Middle East, except in Egypt and Israel [1]. However, reports have recently emerged of their occasional detection in CRE from Saudi Arabia, and the United Arab Emirates [20, 21]. In common with our report, the isolation of KPC-producing K. pneumoniae in Saudi Arabia was associated with recent travel to Egypt, a country where KPC-producing Enterobacterales are endemic [1, 20]. Travel generally, and medical tourism in particular, has frequently been implicated in international importation of multidrug-resistant pathogens [1]. No carbapenemase-encoding genes were detected in 9.4% of the isolates included in this study. It is likely that resistance in those isolates was mediated by non-carbapenemase mechanisms [22]. Tigecycline, fosfomycin, and aminoglycoside were the most active agents against the study isolates. Despite their in vitro activity, these agents’ clinical utility is limited by reduced efficacy in certain infection sites, excessive toxicity, or rapid emergence of resistance [2]. Ceftazidime-avibactam was recently introduced into clinical practice in Qatar. This β-lactam/β-lactamase inhibitor combination is active against most Enterobacterales producing Class A and Class D carbapenemases [2]. However, the introduction of ceftazidime-avibactam to intensive care units in Greece was followed by a change in the pattern of carbapenemases in CRE from blaKPC to blaVIM predominance [23]. Given the background high prevalence of MBL in CRE in Qatar, such agents should be used judiciously to minimize the risk of selection of MBL producers. The study isolates belonged to widely diverse sequence types. Only two international multidrug-resistant high-risk clones were relatively common: E. coli ST38 and K. pneumoniae ST147. However, other important high-risk clones were either infrequent (i.e., E. coli ST131, ST405, and ST648; and K. pneumoniae ST14, and ST258) or absent (e.g., E. coli ST69, ST155, and ST393; and K. pneumoniae ST14) [24]. These observations suggest that rather than clonal expansion, sporadic introductions of CRE and plasmid-mediated dissemination of carbapenemases are the main drivers of CRE epidemiology in Qatar. There are numerous examples of inter-species transmission of carbapenemase genes on mobile genetic elements resulting in in vivo emergence of resistance in individual patients, and also driving institutional, national, and international CRE outbreaks [24]. Our findings highlight the epidemiological global interconnectedness of bacterial antimicrobial. Given Qatar’s demographics and its position as a major hub for international travel, the findings described here have regional and global implications. The molecular epidemiology of carbapenem resistance in Enterobacterales and its underlying mechanisms should be monitored locally, and interpreted in a global context.

Conclusion

The most frequent carbapenemases in CRE from Qatar are NDM and OXA-48-like enzymes. KPC, hitherto rare in the Arabian Peninsula, was present in a minority of the isolates, where all cases were associated with recent overseas medical care. CRE from Qatar belonged to diverse sequence types, suggesting limited local clonal expansion. It appears that the epidemiology of CRE in Qatar is largely driven by a combination of sporadic importation and inter-species transfer of mobile genetic elements. (DOCX 43 kb) (DOCX 83 kb)
  22 in total

1.  NDM-1, OXA-48 and OXA-181 carbapenemase-producing Enterobacteriaceae in Sultanate of Oman.

Authors:  L Dortet; L Poirel; F Al Yaqoubi; P Nordmann
Journal:  Clin Microbiol Infect       Date:  2012-03-08       Impact factor: 8.067

2.  Characterization of KPC-type carbapenemase-producing Klebsiella pneumoniae strains isolated in the Arabian Peninsula.

Authors:  Ágnes Sonnevend; Akela Ghazawi; Dania Darwish; Zulfa AlDeesi; Ali F Kadhum; Tibor Pál
Journal:  J Antimicrob Chemother       Date:  2015-01-20       Impact factor: 5.790

3.  Multi-institute analysis of carbapenem resistance reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaks.

Authors:  Gustavo C Cerqueira; Ashlee M Earl; Christoph M Ernst; Yonatan H Grad; John P Dekker; Michael Feldgarden; Sinéad B Chapman; João L Reis-Cunha; Terrance P Shea; Sarah Young; Qiandong Zeng; Mary L Delaney; Diane Kim; Ellena M Peterson; Thomas F O'Brien; Mary Jane Ferraro; David C Hooper; Susan S Huang; James E Kirby; Andrew B Onderdonk; Bruce W Birren; Deborah T Hung; Lisa A Cosimi; Jennifer R Wortman; Cheryl I Murphy; William P Hanage
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

4.  Molecular characterization of carbapenem- resistant Enterobacteriaceae yields increasing rates of NDM-1 carbapenemases and colistin resistance in an OXA-48- endemic area.

Authors:  Zeynep Cizmeci; Elif Aktas; Baris Otlu; Ozlem Acikgoz; Seyhan Ordekci
Journal:  J Chemother       Date:  2017-05-09       Impact factor: 1.714

Review 5.  The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae.

Authors:  Amy J Mathers; Gisele Peirano; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 6.  Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review.

Authors:  Zaira R Palacios-Baena; Maddalena Giannella; Davide Manissero; Jesus Rodríguez-Baño; Pierluigi Viale; Sara Lopes; Katy Wilson; Rachael McCool; Christopher Longshaw
Journal:  Clin Microbiol Infect       Date:  2020-10-23       Impact factor: 8.067

Review 7.  OXA-48-like carbapenemases: the phantom menace.

Authors:  Laurent Poirel; Anaïs Potron; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2012-04-11       Impact factor: 5.790

8.  Genomic analysis of the first KPC-producing Klebsiella pneumoniae isolated from a patient in Riyadh: A new public health concern in Saudi Arabia.

Authors:  Majed F Alghoribi; Khalifa Binkhamis; Abdulrahman A Alswaji; Ali Alhijji; Aynaa Alsharidi; Hanan H Balkhy; Michel Doumith; Ali Somily
Journal:  J Infect Public Health       Date:  2020-02-14       Impact factor: 3.718

9.  Rapidly disseminating blaOXA-232 carrying Klebsiella pneumoniae belonging to ST231 in India: multiple and varied mobile genetic elements.

Authors:  Chaitra Shankar; Purva Mathur; Manigandan Venkatesan; Agila Kumari Pragasam; Shalini Anandan; Surbhi Khurana; Balaji Veeraraghavan
Journal:  BMC Microbiol       Date:  2019-06-24       Impact factor: 3.605

10.  Molecular characterization of Carbapenem resistant Escherichia coli recovered from a tertiary hospital in Lebanon.

Authors:  Christel Dagher; Tamara Salloum; Sahar Alousi; Harout Arabaghian; George F Araj; Sima Tokajian
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

View more
  5 in total

1.  Fecal Carriage and Molecular Characterization of Carbapenemase-Producing Enterobacterales in the Pediatric Population in Qatar.

Authors:  Andrés Pérez-López; Sathyavathi Sundararaju; Kin Ming Tsui; Hassan Al-Mana; Mohammad Rubayet Hasan; Mohammed Suleiman; Eman Al Maslamani; Omar Imam; Diane Roscoe; Patrick Tang
Journal:  Microbiol Spectr       Date:  2021-11-10

2.  Comparative Genomics Revealed Fluoroquinolone Resistance Determinants and OmpF Deletion in Carbapenem-Resistant Escherichia coli.

Authors:  Wan-Ting Yang; I-Ju Chiu; Yao-Ting Huang; Po-Yu Liu
Journal:  Front Microbiol       Date:  2022-04-18       Impact factor: 6.064

3.  Carbapenem-Resistant Enterobacteriaceae: A Retrospective Review of Presentation, Treatment, and Clinical Outcomes in a Tertiary Care Referral Hospital.

Authors:  Mohammed Al Khamis; Zainab AlMusa; Mai Hashhoush; Narjis Alsaif; Abdul Salam; Manal Atta
Journal:  Cureus       Date:  2022-07-21

4.  Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar.

Authors:  Mazen A Sid Ahmed; Emad Bashir Ibrahim; Jemal M Hamid; Joanne Daghfal; Mohammed A Alyazidi; Aimen H Abdelwahab; Muna A Al-Maslamani; Abdul Latif Al Khal; Hamad Abdel Hadi
Journal:  Oman Med J       Date:  2022-09-30

5.  Evaluation of Rapid Immunochromatographic Tests for the Direct Detection of Extended Spectrum Beta-Lactamases and Carbapenemases in Enterobacterales Isolated from Positive Blood Cultures.

Authors:  Ahmed S Keshta; Nazik Elamin; Mohammad Rubayet Hasan; Andrés Pérez-López; Diane Roscoe; Patrick Tang; Mohammed Suleiman
Journal:  Microbiol Spectr       Date:  2021-12-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.